Arca
Skip to content
Tools
Tools

Acromegaly

Drug research and approvals for acromegaly: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 13 studies of acromegaly are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 5 approved and 4 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 13
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 5
  • EU medicines: 4

Recruiting now

Newest posted first, of 13 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 1

Phase 2 3

Phase 1 or earlier 1

How its trials ended

189 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 47 whose ending is known, 62% met their primary endpoint, 0% missed it and 38% stopped early.

  • Completed, result not reported9148%
  • Met its primary endpoint2915%
  • Status unknown2915%
  • Ongoing2212%
  • Stopped: other or unclear116%
  • Stopped: enrollment or feasibility42%
  • Stopped: sponsor or business decision21%
  • Stopped: lack of efficacy11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 8, 2017A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously…Mycapssa (octreotide)ChiasmaClosed
May 25, 2016Strict IGF-1 control in acromegalySomavertSt Michaels HospitalClosed
Apr 10, 2013An open label, multi-center pasireotide roll-over protocol for patients who have completed a previous novartis-sponsored pasireotide study and are judged by…Pasireotide (SOM230)Recordati Rare DiseasesClosed

FDA orphan designations

Approved first, then open designations, newest first
Sep 25, 2025PalsonifyTreatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an optionCrinetics Pharmaceuticals, Inc.Approved
Jun 26, 2020MYCAPSSA (formerly Octreolin)Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated…Chiesi USA, Inc.Approved
Dec 15, 2014PasireotideTreatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an optionNovartis Pharmaceuticals CorporationApproved
Mar 25, 2003SomavertTreatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies,…Sensus CorporationApproved
Nov 25, 1998Sandostatin LARReduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.Novartis Pharmaceuticals CorporationApproved
Nov 3, 2016H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cy…Treatment of acromegalyAmryt Research Ltd.Designated
Jun 24, 2013VeldoreotideTreatment of acromegalyXeris Pharmaceuticals, lnc.Designated
Dec 7, 2009Octreotide acetate subcutaneous implantTreatment of acromegalyEndo Pharmaceuticals Solutions, Inc.Designated
Nov 4, 2003VapreotideTreatment of acromegalyH3 Pharma, Inc.Designated

Medicines authorised in the EU

Newest first
Apr 23, 2026PalsonifyPaltusotine · orphanCrinetics Pharmaceuticals Europe GmbHEMA ↗
Jun 30, 2025OczyesaOctreotideCamurus ABEMA ↗
Apr 24, 2012SigniforPasireotideRecordati Rare DiseasesEMA ↗
Nov 12, 2002SomavertPegvisomantPfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.